FILTER

Refine your search with the following facets to narrow down your results.

3 Current news of alentis-therapeutics

image description

Alentis Therapeutics closes $105 million Series C funding

Breakthrough treatments for cancer and fibrotic diseases

18-Apr-2023 - Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical-stage biotech company developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors. Alentis announced $105 million in Series C financing. The funding round was led by Jeito Capital together with Novo Holdings ...

cancer fibrosis Series C financing
image description

Alentis Therapeutics Raises USD 67 Million in Series B Financing

Funding to Advance Pipeline of Anti-fibrotic Molecules into the Clinic

16-Jun-2021 - Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, announced that it has raisedUSD67 (CHF60) millionin a Series B financing round. The funding will be used primarily for proof-of-concept clinical trials of Alentis’ first in class, Claudin-1 ...

fibrosis Series B financing

Swiss-French biotech start-up launches

ALENTIS Therapeutics raising CHF 12.5m in a Series A to develop novel therapeutics in advanced liver disease and cancer

02-May-2019 - ALENTIS Therapeutics, a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer, announced the completion of a Series A financing of CHF 12.5million (Euro 11.1m; USD 12.5m). The Swiss venture capital firms BioMedPartners and BB Pureos Bioventures co-led the ...

cancer drug development liver diseases +2